Skip to main content
×
Home

Dextromethorphan-quinidine–responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?

Abstract

The symptoms of emotional dysregulation associated with the syndrome known as pseudobulbar affect (PBA) can be effectively treated by the sigma, glutamate, and serotonergic agent dextromethorphan combined with quinidine. If the same brain circuits affected in PBA are also compromised in related disorders of emotional expression, dextromethorphan-quinidine and other novel sigma-glutamate-serotonin agents could prove to be novel psychopharmacologic treatments for these conditions as well.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Dextromethorphan-quinidine–responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Dextromethorphan-quinidine–responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Dextromethorphan-quinidine–responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
      Available formats
      ×
Copyright
References
Hide All
1. Darwin C. The Expression of the Emotions of Man and Animals. London: John Murray; 1872.
2. Wilson SAK. Some problems in neurology. II: Pathological laughing and crying. J Neurol Psychophathol. 1924; 4: 299333.
3. Cummings J, Gilbart J, Andersen G. Pseudobulbar affect—a disabling but under-recognised consequence of neurological disease and brain injury. Eur Neurol Rev. 2013; 8(2): 7481.
4. Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011; 11(7): 10771088.
5. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry. 2000; 5(4): 290306.
6. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci. 2005; 17(4): 447454.
7. Wortzel HS, Oster TJ, Anderson CA, Arciniegas DB. Pathological laughing and crying: epidemiology, pathophysiology and treatment. CNS Drugs. 2008; 22(7): 531545.
8. Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006; 11(6): 17.
9. Cummings JL. Involuntary emotional expression disorder: definition, diagnosis, and measurement scales. CNS Spectr. 2007; 12(4 Suppl 5): 1116.
10. Parvizi J, Coburn KL, Shillcutt SD, Coffey CE, Lauterbach EC, Mendez MF. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2009; 21(1): 7587.
11. Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying: a link to the cerebellum. Brain. 2001; 124(Pt 9): 17081719.
12. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7): 748751.
13. Stahl SM. The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental Illnesses. CNS Spectr. 2013; 18(2): 6568.
14. Stahl SM. Stahl’s Essential Psychopharmacology. 4th ed. Cambridge, UK: Cambridge University Press; 2013.
15. Stahl SM, Grady M. Stahl’s Illustrated: Drug Abuse and Disorders of Impulsivity. New York: Cambridge University Press; 2012.
16. Stahl SM. Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectr. 2014; 19(5): 357365.
17. Stahl SM. Is impulsive violence an addiction? The habit hypothesis. CNS Spectr. 2015; 20(3): 165169.
18. Grant JE, Kim SW. Brain circuitry of compulsivity and impulsivity. CNS Spectr. 2014; 19(1): 2127.
19. Fineberg NA, Chamberlain SR, Goudriaan AE, et al. New developments in human neurocognition: clinical, genetic and brain imaging correlates of impulsivity and compulsivity. CNS Spectr. 2014; 19(1): 6989.
20. Berlin GS, Hollander E. Compulsivity, impulsivity, and the DSM 5 process. CNS Spectr. 2014; 19(1): 6268.
21. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005; 8(11): 14811489.
22. Everitt BJ, Robbins TW. From ventral to dorsal striatum: devolving views of their roles in drug addiction. Neurosci Biobehav Rev. 2013; 37(9 Pt A): 19461954.
23. American Psychiatric Association. Diagnostic and Statistical Manual of the American Psychiatric Association. 5th ed. Washington, DC: American Psychiatric Press; 2013.
24. Stahl SM. Mechanism of action of dextromethorphan/quinidine: comparison with ketamine. CNS Spectr. 2013; 18(5): 225227.
25. Cummings J, Lyketsos C, Tariot P, et al. Dextromethorphan/quinidine (AVP-923) efficacy and safety for treatment of agitation in Alzheimer’s disease: results from a Phase 3 Study (NCT01584440). Poster#NR11. Presented at: American Association for Geriatric Psychiatry Annual Meeting; March 27–30, 2015; New Orleans, LA.
26. Garcia-Baran D, Johnson TM, Wagner J, Shen J, Geers M. Therapeutic approach of a high functioning individual with traumatic brain injury and subsequent emotional volatility with feathers of pathological laughter and crying with dextromethorphan/quinidine. Medicine (Baltimore). 2016; 95(12): e2886.
27. Messias E, Everett B. Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. Prim Care Companion CNS Disord. 2012; 14(5): PCC.12l01400.
28. Kelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. J Affect Disord. 2014; 167: 333335.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 59
Total number of PDF views: 259 *
Loading metrics...

Abstract views

Total abstract views: 562 *
Loading metrics...

* Views captured on Cambridge Core between 18th November 2016 - 17th November 2017. This data will be updated every 24 hours.